德适-B（02526.HK）今日盘中股价大幅拉升，涨幅达14.23%，市场关注度显著提升。
消息面上，公司自研的AI AutoVision®染色体核型辅助诊断软件正式获得国家药监局第三类医疗器械注册证，这是首张基于大模型技术获批的医疗器械注册证。该注册证审批门槛严苛，获批意味着产品在安全性与临床有效性上获得官方认可，将显著提升其在医院准入、采购选型及未来医保对接方面的竞争力，有望打开规模化入院通道。
此外，该软件基于公司自主研发的iMedImage医学影像基座大模型，能将染色体核型分析的平均时间从34.42分钟大幅缩短至11.19分钟，报告周期从约30天缩短至4-7天。公司2025年财报也显示其营收同比增长133.7%，技术许可收入首次成为第一大收入来源。这些积极进展共同增强了市场对公司未来增长潜力的信心，推动了股价的强势表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.